<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>San Antonio Breast Cancer Symposium</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>ONC-206 shows activity in TNBC models</title>
      <description>
        <![CDATA[Researchers from Chimerix, now part of Jazz Pharmaceuticals, presented preclinical data on ONC-206, a compound that functions as both an agonist of the mitochondrial protease Caseinolytic peptidase P (CLPP) and an antagonist of the G protein-coupled receptor DRD2, in models of triple-negative breast cancer (TNBC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/727324</guid>
      <pubDate>Fri, 19 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727324-onc-206-shows-activity-in-tnbc-models</link>
    </item>
    <item>
      <title>ATNM-400 radioconjugate shows efficacy in resistant breast cancer</title>
      <description>
        <![CDATA[Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies such as tamoxifen. Recurrence is also observed in HER2+ breast cancer, even with HER2-targeted antibodies and antibody-drug conjugates (ADCs), the use of which can be limited by adverse effects such as interstitial lung disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727260</guid>
      <pubDate>Thu, 18 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727260-atnm-400-radioconjugate-shows-efficacy-in-resistant-breast-cancer</link>
    </item>
    <item>
      <title>IRX-5010, anti-PD-L1 synergize in triple-negative breast cancer</title>
      <description>
        <![CDATA[Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative breast cancer (TNBC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/715717</guid>
      <pubDate>Fri, 27 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715717-irx-5010-anti-pd-l1-synergize-in-triple-negative-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>BGB-43395 shows activity in HR+ HER2- breast cancer</title>
      <description>
        <![CDATA[Beigene Co. Ltd. has presented data on a CDK4 selective inhibitor, BGB-43395, for the potential treatment of this cancer type and which would reduce the neutropenia associated with CDK6 inhibition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715666</guid>
      <pubDate>Mon, 23 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715666-bgb-43395-shows-activity-in-hr-her2-breast-cancer</link>
    </item>
    <item>
      <title>ETX-197/BG-68501 shows antitumoral activity in CCNE-amplified cancers</title>
      <description>
        <![CDATA[In tumoral cells, the modulation of the G1/S phases of cell cycle is destabilized by amplification and high expression of cyclin E (CCNE) or by mutation or loss of retinoblastoma 1 (RB1) gene. Cancer cells meeting these characteristics have been sown to be highly sensitive to cyclin-dependent kinase 2 (CDK2) depletion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715468</guid>
      <pubDate>Tue, 17 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715468-etx-197-bg-68501-shows-antitumoral-activity-in-ccne-amplified-cancers</link>
    </item>
    <item>
      <title>CID-078 demonstrates potent antitumoral activity in breast cancer</title>
      <description>
        <![CDATA[Cyclins and cyclin-dependent kinases (CDKs) regulate the activity of E2F and Rb to drive cell cycle progression. Disrupting this interaction has shown lethality in cancer cells harboring alterations that lead to higher expression of E2F1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715418</guid>
      <pubDate>Mon, 16 Dec 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715418-cid-078-demonstrates-potent-antitumoral-activity-in-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-tumor.webp?t=1755066074" type="image/jpeg" medium="image" fileSize="171386">
        <media:title type="plain">Illustration of tumor in breast</media:title>
      </media:content>
    </item>
    <item>
      <title>New cancer data from Bicycle precedes stock drop</title>
      <description>
        <![CDATA[Mixed results for three of Bicycle Therapeutics plc’s zelenectide pevedotin development programs preceded a strong drop in the company’s stock. Bicycle shares (NASDAQ:BCYC) dropped 31.3% on Dec. 13 to close at $13.81 each, the stock’s lowest price in the past 12 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715342</guid>
      <pubDate>Fri, 13 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715342-new-cancer-data-from-bicycle-precedes-stock-drop</link>
    </item>
    <item>
      <title>MBRC-101, an EphA5-targeting ADC with efficacy in models of breast cancer</title>
      <description>
        <![CDATA[Researchers from Mbrace Therapeutics Inc. presented the discovery and preclinical evaluation of MBRC-101, a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5, being developed for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704184</guid>
      <pubDate>Thu, 28 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704184-mbrc-101-an-epha5-targeting-adc-with-efficacy-in-models-of-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Antibody-drug-conjugate.webp?t=1632171505" type="image/png" medium="image" fileSize="395059">
        <media:title type="plain">Antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>Io Therapeutics presents second-generation RARγ nuclear receptor agonist for breast cancer</title>
      <description>
        <![CDATA[Retinoic acid receptor-γ (RARγ) agonism is a key factor in CD8 T-cell-mediated immunity to infectious pathogens. The lack of studies on the effects of RARγ agonists on in vivo tumor growth of triple-negative (TNBC) or HER2+ breast cancers make it necessary to investigate whether RARγ could play a critical role in T-cell-mediated immunity in these breast cancers, using novel RARγ nuclear agonists.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704082</guid>
      <pubDate>Thu, 28 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704082-io-therapeutics-presents-second-generation-rar-nuclear-receptor-agonist-for-breast-cancer</link>
    </item>
    <item>
      <title>OKI-219 overcomes PI3Kα resistance in combination </title>
      <description>
        <![CDATA[PI3Kα H1047R accounts for one-third of all PI3Kα mutations and is associated with treatment resistance to targeted therapies in breast cancer treatment. In addition, treatment with selective PI3Kα inhibitors often results in significant adverse events such as hyperglycemia due to on-target toxicity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704045</guid>
      <pubDate>Wed, 27 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704045-oki-219-overcomes-pi3k-resistance-in-combination</link>
    </item>
    <item>
      <title>BBO-10203 inhibits RAS-driven PI3Kα activity in tumor cells without changes in glucose metabolism</title>
      <description>
        <![CDATA[Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704043</guid>
      <pubDate>Wed, 27 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704043-bbo-10203-inhibits-ras-driven-pi3k-activity-in-tumor-cells-without-changes-in-glucose-metabolism</link>
    </item>
    <item>
      <title>BLU-222 shows synergy with CDK4/6 inhibitors in models of CDK4/6 inhibitor-resistant breast cancer</title>
      <description>
        <![CDATA[Researchers from Blueprint Medicines Corp. presented data from a study that aimed to assess the effects of combining cyclin-dependent kinase 2 (CDK2) inhibitor BLU-222 with CDK4/6 inhibitors, such as palbociclib or ribociclib, to overcome CDK4/6 inhibitor resistance in HR-positive/HER2-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704023</guid>
      <pubDate>Fri, 22 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704023-blu-222-shows-synergy-with-cdk4-6-inhibitors-in-models-of-cdk4-6-inhibitor-resistant-breast-cancer</link>
    </item>
    <item>
      <title>CDK4/6 degrader BTX-9341 shows promise for HR+/HER2- breast cancer</title>
      <description>
        <![CDATA[The inhibition of cyclin-dependent kinase 4 (CDK4) and CDK6 is a useful strategy to treat hormone receptor (HR)+/HER2+ breast cancer, but patients may develop resistance through different mechanisms. As reported at the recent San Antonio Breast Cancer Symposium, researchers from Biotheryx Inc. have synthesized a new CDK4/6 degrader – BTX-9341 – to address the problem of therapeutic resistance in breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703701</guid>
      <pubDate>Wed, 13 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703701-cdk4-6-degrader-btx-9341-shows-promise-for-hr-her2-breast-cancer</link>
    </item>
    <item>
      <title>Anti-SFRP2 MAb increases tumor apoptosis and inhibits metastases in models of TNBC</title>
      <description>
        <![CDATA[Researchers from Medical University of South Carolina aimed to evaluate the potential of secreted frizzled-related protein 2 (SFRP2) as a promising novel target for breast cancer using a newly developed humanized monoclonal antibody to SFRP2 (hSFRP2 MAb) in models of this disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703697</guid>
      <pubDate>Wed, 13 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703697-anti-sfrp2-mab-increases-tumor-apoptosis-and-inhibits-metastases-in-models-of-tnbc</link>
    </item>
    <item>
      <title>Stock price reflects Intensity of enthusiasm for phase II breast cancer prospect</title>
      <description>
        <![CDATA[Injecting a combination of cisplatin and vinblastine – engineered by way of the company’s Dfuserx platform – turned out to be just the ticket for early stage breast cancer in the phase II study called Invincible conducted by Intensity Therapeutics Inc. Shares of the Shelton, Conn.-based firm (NASDAQ:INTS) closed Dec. 8 at $6.88, up $2.68, or 63%, having traded as high as $11.44, thanks to Wall Street’s satisfaction with the data testing INT230-6, which emerged during the San Antonio Breast Cancer Symposium.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703610</guid>
      <pubDate>Fri, 08 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703610-stock-price-reflects-intensity-of-enthusiasm-for-phase-ii-breast-cancer-prospect</link>
    </item>
    <item>
      <title>Arvinas, Pfizer broaden scope of ER-targeting therapy after impressive phase Ib breast cancer readout</title>
      <description>
        <![CDATA[While early stage and involving a relatively small patient population, the interim phase Ib readout from the combination cohort testing estrogen receptor (ER)-targeting candidate vepdegestrant in combination with CDK4/6 inhibitor Ibrance (palbociclib) in heavily pretreated patients with ER-positive/HER2-negative breast cancer was impressive enough to prompt partners Arvinas Inc. and Pfizer Inc. to expand development work on the program. The results also struck a chord on the Street, with shares of Arvinas (NASDAQ:ARVN) gaining 31% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703509</guid>
      <pubDate>Wed, 06 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703509-arvinas-pfizer-broaden-scope-of-er-targeting-therapy-after-impressive-phase-ib-breast-cancer-readout</link>
    </item>
    <item>
      <title>Conference data for Dec. 12, 2022: SABCS</title>
      <description>
        <![CDATA[New and updated clinical data presented by biopharma firms at the <span style="box-sizing: inherit; color: rgb(0, 0, 0); letter-spacing: normal; orphans: 2; text-align: left; white-space: normal; widows: 2; word-spacing: 0px; display: inline !important;">San Antonio Breast Cancer Symposium</span>, including: Ambrx, Astrazeneca, Celcuity, Treadwell, Zymeworks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692329</guid>
      <pubDate>Mon, 12 Dec 2022 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692329-conference-data-for-dec-12-2022-sabcs</link>
    </item>
    <item>
      <title>Conference data for Dec. 9, 2022: SABCS</title>
      <description>
        <![CDATA[New and updated clinical data presented by biopharma firms at the San Antonio Breast Cancer Symposium, including: Astrazeneca, Context, Dantari, Exelixis, G1, Intensity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692295</guid>
      <pubDate>Fri, 09 Dec 2022 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692295-conference-data-for-dec-9-2022-sabcs</link>
    </item>
    <item>
      <title>In reversal of fortune, efti shows OS promise for metastatic breast cancer</title>
      <description>
        <![CDATA[Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501377</guid>
      <pubDate>Tue, 15 Dec 2020 15:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501377-in-reversal-of-fortune-efti-shows-os-promise-for-metastatic-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-awareness.webp?t=1607544718" type="image/png" medium="image" fileSize="491584">
        <media:title type="plain">Breast cancer awareness</media:title>
      </media:content>
    </item>
    <item>
      <title>In reversal of fortune, efti shows OS promise for metastatic breast cancer</title>
      <description>
        <![CDATA[Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501221</guid>
      <pubDate>Thu, 10 Dec 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501221-in-reversal-of-fortune-efti-shows-os-promise-for-metastatic-breast-cancer</link>
    </item>
    <item>
      <title>Conference data for Dec. 10, 2020: SABCS</title>
      <description>
        <![CDATA[New and updated preclinical and clinical data presented by biopharma firms at the San Antonio Breast Cancer Symposium, Dec. 8-11, including: Amunix, Astrazeneca, Athenex, Beyondspring, Bold, Briacell, Daiichi Sankyo, Eli Lilly, Evelo, Greenwich, Immutep, Infinity, Medsir, Novartis, Oncolytics, Pharmabcine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501138</guid>
      <pubDate>Thu, 10 Dec 2020 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501138-conference-data-for-dec-10-2020-sabcs</link>
    </item>
    <item>
      <title>Greenwich soars nearly 1,000% on strong breast cancer survival rates</title>
      <description>
        <![CDATA[New five-year breast cancer survival data from Greenwich Lifesciences Inc. ignited its stock for a wild ride that climbed nearly 1,000% upward Dec. 9, marking one of the biotech sector’s biggest single-day gains in 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501148</guid>
      <pubDate>Wed, 09 Dec 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501148-greenwich-soars-nearly-1000-on-strong-breast-cancer-survival-rates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-awareness.webp?t=1607544718" type="image/png" medium="image" fileSize="491584">
        <media:title type="plain">Breast cancer awareness</media:title>
      </media:content>
    </item>
    <item>
      <title>Verzenio continues to show benefit, but time may topple monarchE</title>
      <description>
        <![CDATA[Data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) – held, of course, in cyberspace and not San Antonio this year – added to the evidence that adding Verzenio (abemaciclib, Eli Lilly and Co.) to endocrine therapy for up to two years benefited women with high-risk, early stage hormone receptor-driven and HER2-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501143</guid>
      <pubDate>Wed, 09 Dec 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501143-verzenio-continues-to-show-benefit-but-time-may-topple-monarche</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Dec-2020/Science-breast-cancer-cell-12-9.webp?t=1607542510" type="image/png" medium="image" fileSize="570840">
        <media:title type="plain">Breast cancer cell</media:title>
        <media:description type="plain">Breast cancer cell. Credit: Bruce Wetzel and Harry Schaefer, NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>Guardant360 liquid biopsy quickly identifies targetable mutations in breast cancer</title>
      <description>
        <![CDATA[The Guardant360 assay accurately detected genomic alterations that permit patient matching to targeted therapies, according to a presentation of the plasmaMATCH study at the 2019 San Antonio Breast Cancer Symposium. The study is the largest ever performed for a liquid biopsy. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/431920</guid>
      <pubDate>Thu, 19 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431920-guardant360-liquid-biopsy-quickly-identifies-targetable-mutations-in-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/guardant-health-G360-12-19.webp?t=1576791556" type="image/png" medium="image" fileSize="107739">
        <media:title type="plain">guardant-health-G360-12-19.png</media:title>
        <media:description type="plain">Credit: Guardant Health Inc.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
